Close

Anti-MYH14 DNA-encoded mAb (DMAb), pVAX1 (DMAb-2543-FY)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-MYH14 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • MYH14
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-2543-FY CBFYM-0068 Mouse Human IgG1, k Full length native protein (purified) (Human)
DMAb-2544-FY CBFYM-0361 Mouse Human IgG2b Chicken pectoralis-derived Myosin
DMAb-2545-FY CBFYM-0768 Mouse Human IgG1
DMAb-2546-FY CBFYM-2921 Mouse Human Chicken muscle cells
DMAb-2547-FY CBFYM-2922 Human Human Fusion protein of a domain of murine mFLJ00279 (amino acid residues 958-1201, MW 28 kDa) expressed in E. coli
DMAb-2548-FY CBFYM-2923 Mouse Human IgG Recognizes human myosin heavy chain
DMAb-2549-FY CBFYM-2924 Mouse Human IgG KLH conjugated synthetic peptide encompassing a sequence within the N-term region of human myosin heavy chain
DMAb-2550-FY CBFYM-2925 Mouse Human IgG Purified human cardiac myosin heavy chain
DMAb-2551-FY CBFYM-2926 Mouse Human IgM Smooth muscle myosin
DMAb-2552-FY CBFYM-2927 Mouse Human IgG1 Myosin isolated from rabbit skeletal muscle
DMAb-2553-FY CBFYM-2928 Rabbit Human IgG
DMAb-2554-FY CBFYM-2929 Mouse Human IgG1 Rabbit muscle myosin
DMAb-2555-FY CBFYM-2930 Mouse Human IgG1 Native myosin heavy chain from muscle

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-MYH14 DNA-encoded mAb (DMAb), pVAX1 (DMAb-2543-FY). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.